source
- Expedition Therapeutics secures $115M Series B to advance China-origin COPD drugExpedition Therapeutics, a biotech that licenses drugs from Chinese firms, announced a $115 million Series B financing that will fund mid-stage testing of its experimental COPD candidate. The fund…
- Fecal microbiome transplant boosts peanut tolerance sixfold in early trialResearchers at Boston Children’s Hospital conducted a small open‑label phase 1 trial in which 15 adult participants received oral encapsulated fecal microbiome transplantation to test safety and ef…